Johnson & Johnson Maintains Steady Growth Amidst Headwinds - Upbeat Q4 Guidance Signals Confidence in Future.

# Johnson & Johnson (JNJ) Beats Expectations: Strong Growth Despite Challenges | Investing Insights Podcast Discover why Johnson & Johnson stock remains resilient despite recent profit-taking. In this episode, we analyze JNJ's impressive Q4 2025 performance, with revenue jumping 9.1% to $24.56 billion and management's optimistic 2026 guidance exceeding Wall Street projections. Learn how oncology powerhouses Darzalex and Tremfya are driving growth while the company navigates Stelara competition and litigation challenges. With analysts maintaining a "Moderate Buy" consensus and a reliable 2.4% dividend yield, find out why JNJ continues to attract long-term investors seeking stability in an uncertain market. Subscribe now for more expert analysis on blue-chip stocks that can weather market volatility. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.